Clinical Trials Directory

Trials / Unknown

UnknownNCT01011621

Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis

Comparative Evaluation of the Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in the Treatment of Pediatric and Adult Dermatosis

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
170 (estimated)
Sponsor
Mantecorp Industria Quimica e Farmaceutica Ltd. · Industry
Sex
All
Age
12 Years – 60 Years
Healthy volunteers
Not accepted

Summary

Topical corticosteroids are largely used in dermatology. The major problem related to their use is that the same mechanisms underlying their therapeutic effects (antiinflammatory and antiproliferative) may lead to adverse events. Conditions sensitive to corticosteroids require formulations with mild to moderate potency while high-potency corticosteroids era required in less responsive conditions. The aim of the present study is to compare the safety and efficacy of prednisolone acetate 0.5% cream (mild-potency non-fluoridated corticosteroid) versus betamethasone valerate 0.1% cream (high-potency fluoridated corticosteroid) in the treatment of mild to moderate cortisosensitive dermatosis (atopic dermatitis, contact dermatitis, seborrheic dermatitis and psoriasis). The study hypothesis is that 0.5% prednisolone cream will be as effective as 0.1% betamethasone cream and will be an alternative option to treat corticosensitive dermatosis in body areas where the use of fluoridated corticosteroids is contraindicated, such as the face.

Conditions

Interventions

TypeNameDescription
DRUG0.5% prednisolone acetate creamSmall amount applied over the lesion twice a day for 14 days.
DRUG0.1% betamethasone valerate creamSmall amount applied over the lesion twice a day for 14 days.

Timeline

Start date
2010-02-01
Primary completion
2012-02-01
First posted
2009-11-11
Last updated
2009-11-11

Source: ClinicalTrials.gov record NCT01011621. Inclusion in this directory is not an endorsement.